Filing summary
Entity mismatch: The request identifies Assembly Biosciences, Inc., but the supplied Form 10-K is for Ventrus Biosciences, Inc. It covers the fiscal year ended December 31, 2013 and was signed March 31, 2014. The filing describes Ventrus as a development-stage specialty pharmaceutical company focused on gastrointestinal treatments.
Financial performance and position
| Metric | 2013 | 2012 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $15.03 million | $19.51 million |
| General and administrative expense | $4.58 million | $5.34 million |
| Operating loss | $19.60 million | $24.86 million |
| Net loss | $19.40 million | $24.79 million |
| Basic and diluted loss per share | $1.00 | $1.94 |
| Net cash used in operating activities | $17.80 million | $21.38 million |
- Cash and cash equivalents were $27.06 million at December 31, 2013, versus $20.49 million a year earlier. Current assets were $27.12 million and current liabilities $2.64 million, implying working capital of approximately $24.49 million.
- Total assets were $27.13 million; stockholders’ equity was $24.49 million. The balance sheet reported no debt at year-end; liabilities consisted of accounts payable and accrued expenses.
- Financing activities provided $24.37 million in 2013, primarily from equity offerings. The company reported $94.8 million of cumulative net proceeds from public offerings and private placements since inception. It raised a further approximately $1.8 million net through its at-the-market program in January 2014.
- Management estimated existing cash, including the January 2014 proceeds, would fund operations through initial launch of VEN 307 and into the second quarter of 2016, subject to assumptions and regulatory outcomes. The company reported no product sales, operating losses since inception, and an accumulated development-stage deficit of $111.72 million.
Changes versus the prior year
- Net loss narrowed by approximately $5.39 million, while operating expenses declined by about 21%. R&D expense fell 23%, primarily because the company wound down VEN 309, partially offset by increased VEN 307 spending. G&A expense declined 14%, mainly due to lower stock-based compensation, partly offset by higher legal costs, including class-action defense.
- Operating cash use decreased by approximately $3.58 million. Cash increased by $6.57 million during 2013, supported by equity financing.
- In November 2013, Ventrus licensed Therabiome’s pH-sensitive intestinal drug-delivery platform, designated VEN 310, for an upfront nonrefundable $300,000 and future development, regulatory and sales-based payments.
Business, outlook and material developments
- VEN 307 (topical diltiazem): The lead candidate for anal-fissure pain. S.L.A. Pharma’s European Phase III trial reported statistically significant improvement over placebo on the primary pain endpoint. However, the second pivotal U.S. Phase III trial, initiated in late 2012, showed no significant improvement over placebo on its primary endpoint; secondary endpoints were reported as parallel to the primary result. These U.S. top-line results were disclosed in the first quarter of 2014, after the reporting year.
- Ventrus said it had requested an FDA pre-NDA meeting to determine next steps and, depending on FDA feedback, expected to file an NDA in the third quarter of 2014. The FDA had previously indicated it preferred a second pivotal study and additional safety data; whether the existing evidence would suffice remained uncertain. The filing also said the company did not expect to seek a healing claim on the label.
- Two dermal safety studies reported in September 2013 found VEN 307 safe and well tolerated. A pharmacokinetic study showed systemic exposure of approximately 10% of oral diltiazem exposure. These findings do not resolve the efficacy uncertainty from the U.S. pivotal trial.
- VEN 308 (topical phenylephrine): Has FDA orphan designation for fecal incontinence associated with ileal pouch anal anastomosis. The company was not actively pursuing development at the time of the filing; it contemplated technical work on a twice-daily formulation before deciding whether to proceed.
- VEN 310: The newly licensed delivery platform was intended to target release in the intestine, with potential applications including C. difficile-associated disease, VRE colonization, inflammatory bowel disease and oral vaccines. These were development concepts, not established products or clinical results.
- The company expected continued operating losses and increasing development and commercialization-related costs. It stated that additional capital could be needed if assumptions proved incorrect, development expanded, or VEN 307 was not approved or successfully launched. Future financing might dilute shareholders or be unavailable on acceptable terms.
- VEN 307 and VEN 308 are licensed from S.L.A. Pharma, with royalties and regulatory milestone obligations; the filing describes potential S.L.A. milestones of up to $20 million. VEN 310 carries separate Therabiome milestone and royalty obligations. Key risks include regulatory delay or rejection, clinical failure, reliance on third-party manufacturers and collaborators, limited commercial infrastructure, and competition.
- Two purported securities class actions related to statements about former candidate VEN 309 were consolidated. Ventrus had moved to dismiss; the motion was under submission, and the company could not estimate a possible loss. No other material legal proceedings were reported.
Most important facts for investors to verify
- Confirm the correct issuer: the supplied filing is Ventrus Biosciences, not Assembly Biosciences.
- Review the full U.S. VEN 307 Phase III results and the outcome of the FDA pre-NDA meeting, including whether another pivotal trial is required and whether an NDA is supportable.
- Assess cash burn, the assumptions behind management’s runway estimate through Q2 2016, and financing needs following the January 2014 equity raise.
- Verify the terms and potential financial impact of S.L.A. Pharma and Therabiome milestones, royalties and other license obligations.
- Monitor the securities litigation, VEN 310 development spending, and whether Ventrus resumes development of VEN 308.